

## Ardelyx to Present at the Jefferies 2018 Global Healthcare Conference

May 29, 2018

wire! - Ardely, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present a company overview at the Jefferies Global Healthcare Conference on Tuesday, June 5, 2018 at 230 p.m. ET in New York City.



To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at it andelyx.com. A replay of the webcast will be available on the Ardelyx website for 60 days following the conference.

About Ardelys, Inc.
Ardelys, is locused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. Ardelys's renal pipeline includes the Phase 3 development of tempanor for the treatment of hypephosphatemia in people with end-slage renal disease who are on dalaysis and RDX013, a potassium secretagogue program for the potential treatment of hypephosphatemia in people with end-slage renal diseases who are on dalaysis and RDX013, a potassium secretagogue program for the potential treatment of hip potassium, or hyperhatemia, problem among certain patients with kidney and/or heart disease. In addition, Ardelys has completed Phase 3 development of tempanor for the treatment of implication and anticipates submitting a New Drug Application to the U.S. Food and Drug Administration for this indication in the second half of 2118. To efficiently bring its treatments to market, Ardelys is pussing strategic collaborations in the U.S. and other countries, including through established agreements with Kyowa Hakko Kirin in Japan, Fosum Pharma in Chrina and Kright Therspeutics in Canada. For more information, please visit your analysis of commendation of the second half of 2118. To efficiently bring its treatments to market, Ardelys is pussing strategic collaborations in the U.S. and other countries, including through established agreements with Kyowa Hakko Kirin in Japan, Fosum Pharma in Chrina and Kright Therspeutics in Canada. For more information, please visit your analysis of control with us on Twitter @Ardelys.

\*\*The Commendation of the Commendation

SOURCE Ardelyx

Monique Allaire, THRUST IR, 781-631-0759, monique@thrustir.com; Alicia Davis, THRUST IR, 910-620-3302, alicia@thrustir.com